Please login to the form below

Not currently logged in
Email:
Password:

Bispecific antibodies

This page shows the latest Bispecific antibodies news and features for those working in and with pharma, biotech and healthcare.

Hal Barron touts new drive to improve GSK’s research output

Hal Barron touts new drive to improve GSK’s research output

In February it also signed a major $4.2bn in-licensing partnership with Germany’s Merck, centred on a potential ‘next big thing’ in oncology, bispecific antibodies.

Latest news

More from news
Approximately 4 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Deal Watch December 2016 Deal Watch December 2016

    511. BioInvent (Sweden). Pfizer (US). Research collaboration. Development of immuno-regulatory antibodies targeting tumour-associated myeloid cells. ... Technology. Merus. Incyte. $3, 000m. $120m plus $80m equity. Bispecific antibodies.

  • Deal Watch September 2016 Deal Watch September 2016

    In return, Zymeworks is licensing immuno-oncology antibodies from Daiichi Sankyo, in exchange for royalties on sales. ... 624. EngMab / Celgene. Acquisition corporate. T cell bispecific antibodies that bind simultaneously to a tumour antigen and the T

  • Deal Watch June 2016 Deal Watch June 2016

    2 T-cell engaging XmAb bispecific antibodies: XmAb14045 for AML and XmAb13676 for B-cell malignancies (preclinical) and other rights. ... licence. 125. EpimAb Biotherapeutics/ Innovent Biologics. Fabs-In-Tandem immunoglobulin platform to develop multiple

  • Deal Watch April 2016 Deal Watch April 2016

    The collaboration provides GSK with a platform technology to develop bispecific antibodies. ... 125 . Enumeral (US). Pieris (DE). License &option to further programme. Discovery state 388D4 programme of PD1 Monoclonal Antibodies immunotherapies.

  • Deal Watch January 2016 Deal Watch January 2016

    The second deal closed by Sanofi was with Innate Pharma to create new bispecific antibodies, which aim to kill tumour cells through the activation of NKp46. ... 502.3. Innate Pharma/ Sanofi. Collaboration . Collaboration to develop 2 bispecific NK cell

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • F-star hires ex-BMS immuno-oncology leader

    Dr Kayitalire’s background will be of benefit to F-star, as it looks to advance its bispecific antibody pipeline in oncology. ... pipeline. As we saw at the recent ASCO meeting, bispecific antibodies are leading a paradigm shift in cancer care and the

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics